Image (1e5a0f45 86aa 498a 9cc3 9f7acc210ed6 01)
Theophylline Tablet, Extended Release
Product Images NDC 72578-174
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Theophylline (NDC 72578-174). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Viona Pharmaceuticals Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
300 mg (1e5a0f45 86aa 498a 9cc3 9f7acc210ed6 02)
This is a description for Theophylline Extended-Release Tablets with a strength of 300 mg. The package contains 100 tablets in a child-resistant packaging. The usual dosage information can be found in the package insert. The tablets should be stored in a controlled room temperature between 15°C to 30°C. The product is manufactured by Zydus Lifesciences Ltd. in Ahmedabad, India, and distributed by Viona Pharmaceuticals Inc. in Cranford, NJ 07016.*
450 mg (1e5a0f45 86aa 498a 9cc3 9f7acc210ed6 03)
Each uncoated extended-release tablet contains Theophylline (Anhydrous) USP, 450 mg. The usual dosage of Theophylline can be found in the package insert for prescribing information. Storage instructions include keeping the tablets at 20°C to 25°C (66°F to 77°F) with permitted excursions between 15°C to 30°C (59°F to 86°F). Dispense in a well-closed container with child-resistant closure. Manufactured by Zydus Lifesciences Ltd. in Ahmedabad, India. Distributed by Viona Pharmaceuticals Inc. Rev. 0224.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
